Home Cart Sign in  
Chemical Structure| 522-17-8 Chemical Structure| 522-17-8

Structure of Deguelin
CAS No.: 522-17-8

Chemical Structure| 522-17-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Deguelin is a naturally occuring Akt inhibitor purified from the herbs of Derris robusta, which downregulates Akt phosphorylation and shows anticancer effect.

Synonyms: (-)-Deguelin; (-)-cis-Deguelin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Deguelin

CAS No. :522-17-8
Formula : C23H22O6
M.W : 394.42
SMILES Code : O=C1[C@]2([H])[C@](COC3=CC(OC)=C(OC)C=C32)([H])OC4=C5C=CC(C)(C)OC5=CC=C14
Synonyms :
(-)-Deguelin; (-)-cis-Deguelin
MDL No. :MFCD01740600
InChI Key :ORDAZKGHSNRHTD-UXHICEINSA-N
Pubchem ID :107935

Safety of Deguelin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Deguelin

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • PI3K

  • Akt

In Vitro:

Cell Line
Concentration Treated Time Description References
Eca109 1, 2, 5 μM 24 h Deguelin induced G2/M phase cell cycle arrest and polyploidy in Eca109 cells PMC5832566
KYSE150 1, 2, 5 μM 24 h Deguelin induced G2/M phase cell cycle arrest and polyploidy in KYSE150 cells PMC5832566
Human Retinal Endothelial Cells (HRECs) 0~10 µM 48 h To evaluate the cytotoxic effect of deguelin on HRECs, results showed that deguelin did not affect the viability of HRECs up to 1 µM. PMC4514118
HEK 293 cells 0~10 µM 16 h To evaluate the effect of deguelin on HIF-1α transcriptional activity, results showed that deguelin did not affect HIF-1α transcriptional activity up to 1 µM, but reduced it at 10 µM. PMC4514118
PanC-1 cells 62μM 24 h To evaluate the cytotoxicity of deguelin in pancreatic cancer cells, results showed that deguelin significantly inhibited the survival of PanC-1 cells. PMC3530646
COLO-357 cells 27μM 24 h To evaluate the cytotoxicity of deguelin in pancreatic cancer cells, results showed that deguelin significantly inhibited the survival of COLO-357 cells. PMC3530646
L3.6pl cells 12μM 24 h To evaluate the cytotoxicity of deguelin in pancreatic cancer cells, results showed that deguelin significantly inhibited the survival of L3.6pl cells. PMC3530646
A549 50 μM 24 h Deguelin decreased the mRNA levels of HR molecules, especially Rad51, indicating that deguelin can inhibit the function of FBXO22 PMC10830569
H1299 50 μM 24 h Deguelin decreased the mRNA levels of HR molecules, especially Rad51, indicating that deguelin can inhibit the function of FBXO22 PMC10830569
MCF-7 10^-8 M to 10^-6 M 3 days Deguelin significantly reduced the viability of MCF-7 cells and inhibited their anchorage-dependent colony formation ability. PMC3638119
MDA-MB-231 10^-8 M to 10^-6 M 3 days Deguelin significantly reduced the viability of MDA-MB-231 cells and inhibited their anchorage-dependent colony formation ability. PMC3638119
U-2 OS human osteosarcoma cells 0, 5, 10, 15, 20 μM 24 and 48 h Deguelin significantly inhibited the migration and invasion of U-2 OS human osteosarcoma cells, which was associated with a reduction in the activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). PMC6271177
NCI-1975 cells 5, 10, 20, 50 μM 24 h Deguelin induces apoptosis of NCI-1975 cells through a ROS-driven Akt pathway, which can be partially reversed by NAC. PMC4349657
NCI-H446 cells 5, 10, 20, 50 μM 24 h Deguelin shows similar cytotoxic effects on NCI-H446 cells as on NCI-1975 cells. PMC4349657
H1299 cells 100 nM 12 h Suppressed HIF-1α protein expression and VEGF mRNA expression, reducing the survival and angiogenic potential of radioresistant lung cancer cells PMC2646382
H226B cells 100 nM 12 h Suppressed HIF-1α protein expression and VEGF mRNA expression, reducing the survival and angiogenic potential of radioresistant lung cancer cells PMC2646382

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice KYSE150 and Eca109 xenograft model Intraperitoneal injection 4 mg/kg Daily until the end of the experiment Deguelin significantly inhibited the growth of KYSE150 and Eca109 xenograft tumors PMC5832566
C57BL/6 mice Oxygen-Induced Retinopathy (OIR) model Intravitreal injection 0.1 µM Single injection, continued until P17 To evaluate the inhibitory effect of deguelin on retinal neovascularization in the OIR model, results showed that deguelin significantly reduced retinal neovascularization. PMC4514118
nude mice orthotopic implantation of PanC-1-luc cells intraperitoneal injection 5mg/kg daily for 37 days To evaluate the inhibitory effect of deguelin on pancreatic tumor growth and metastasis, results showed that deguelin significantly inhibited tumor growth and metastasis, and induced apoptosis. PMC3530646
BALB/c nude mice Tumor xenograft model Oral 4 mg/kg Every other day, throughout the experimental period Deguelin slowed the growth of xenograft tumors, especially when combined with radiotherapy, showing significant growth inhibition PMC10830569
Nude mice MCF-7 cell xenograft model Oral gavage 4 mg/kg Twice daily for 45 days Deguelin significantly inhibited the growth of MCF-7 xenograft tumors and induced apoptosis. PMC3638119

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.68mL

2.54mL

1.27mL

25.35mL

5.07mL

2.54mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories